Demonstration of a low-molecular-weight natriuretic factor in uremic serum.

J. Bourgoignie,F. Weisser,D. Rolf,S. Klahr,N. Bricker

Abstract:

What problem does this paper attempt to address?

Longitudinal Clinical and Radiographic Evaluation Reveals Interleukin-6 As an Indicator of Persistent Pulmonary Injury in COVID-19

Baolin Liao,Zhipeng Liu,Libo Tang,Linghua Li,Qingxin Gan,Haiyan Shi,Qian Jiao,Yujuan Guan,Min Xie,Xi He,Han Zhao,Weilie Chen,Yanxia Liu,Liya Li,Yaping Wang,Yi Cao,Yaling Shi,Yongyin Li,Chunliang Lei

DOI: https://doi.org/10.7150/ijms.49728

2021-01-01

International Journal of Medical Sciences

Abstract:Rationale: Previous studies of coronavirus disease 2019 (COVID-19) were mainly focused on cross-sectional analysis. In this study, we sought to evaluate the dynamic changes of immunological and radiographic features, and the association with the outcome of pulmonary lesions in COVID-19 patients. Methods: Peripheral blood samples and radiographic data were collected longitudinally for up to 8 weeks from 158 laboratory-confirmed COVID-19 patients. The chest computed tomography (CT) scans were scored based on a semi-quantification assessment according to the extent of pulmonary abnormalities; the temporal change of the immunological and radiographic features was analyzed. Results: Compared with mild and moderate patients, severe patients had significantly decreased counts of lymphocytes, CD4+ T cells, CD8+ T cells, and CD19+ B cells but dramatically elevated counts of neutrophils and levels of interleukin (IL)-6. Sequential monitoring showed a sustained increase in lymphocytes counts and significantly decreased levels of IL-6 in severe patients during the disease course. Notably, patients with persistent pulmonary lesions (CT score ≥ 5 in week 8) showed high levels of IL-6 during the follow-up period, compared with those with recovery lesions (CT score < 5 in week 8). More importantly, the peak expression of IL-6 prior to the aggravated lung injury was mainly found in patients with persistent lesions, and multivariate analysis showed that IL-6 level upon admission was an independent factor associated with the persistent pulmonary injury. Conclusion: Prolonged elevation of IL-6 is associated with persistent pulmonary lesions in COVID-19 patients. Sequential monitoring and timely intervention of IL-6 may favor the clinical management of COVID-19.
Impact of Coronavirus Disease 2019 on Pulmonary Function in Early Convalescence Phase

Yiying Huang,Cuiyan Tan,Jian Wu,Meizhu Chen,Zhenguo Wang,Liyun Luo,Xiaorong Zhou,Xinran Liu,Xiaoling Huang,Shican Yuan,Chaolin Chen,Fen Gao,Jin Huang,Hong Shan,Jing Liu

DOI: https://doi.org/10.1186/s12931-020-01429-6

IF: 5.8

2020-01-01

Respiratory Research

Abstract:Objective This study investigated the influence of Coronavirus Disease 2019 (COVID-19) on lung function in early convalescence phase. Methods A retrospective study of COVID-19 patients at the Fifth Affiliated Hospital of Sun Yat-sen University were conducted, with serial assessments including lung volumes (TLC), spirometry (FVC, FEV1), lung diffusing capacity for carbon monoxide (DLCO),respiratory muscle strength, 6-min walking distance (6MWD) and high resolution CT being collected at 30 days after discharged. Results Fifty-seven patients completed the serial assessments. There were 40 non-severe cases and 17 severe cases. Thirty-one patients (54.3%) had abnormal CT findings. Abnormalities were detected in the pulmonary function tests in 43 (75.4%) of the patients. Six (10.5%), 5(8.7%), 25(43.8%) 7(12.3%), and 30 (52.6%) patients had FVC, FEV1, FEV1/FVC ratio, TLC, and DLCO values less than 80% of predicted values, respectively. 28 (49.1%) and 13 (22.8%) patients had PImax and PEmax values less than 80% of the corresponding predicted values. Compared with non-severe cases, severe patients showed higher incidence of DLCO impairment (75.6%vs42.5%, p = 0.019), higher lung total severity score (TSS) and R20, and significantly lower percentage of predicted TLC and 6MWD. No significant correlation between TSS and pulmonary function parameters was found during follow-up visit. Conclusion Impaired diffusing-capacity, lower respiratory muscle strength, and lung imaging abnormalities were detected in more than half of the COVID-19 patients in early convalescence phase. Compared with non-severe cases, severe patients had a higher incidence of DLCO impairment and encountered more TLC decrease and 6MWD decline.
Quantitative Characterization of Respiratory Patterns on Dynamic Higher Temporal Resolution MRI to Stratify Postacute Covid‐19 Patients by Cardiopulmonary Symptom Burden

Lea Azour,Henry Rusinek,Artem Mikheev,Nicholas Landini,Mahesh Bharath Keerthivasan,Christoph Maier,Barun Bagga,Mary Bruno,Rany Condos,William H. Moore,Hersh Chandarana

DOI: https://doi.org/10.1002/jmri.29352

IF: 4.4

2024-03-15

Journal of Magnetic Resonance Imaging

Abstract:Background Postacute Covid‐19 patients commonly present with respiratory symptoms; however, a noninvasive imaging method for quantitative characterization of respiratory patterns is lacking. Purpose To evaluate if quantitative characterization of respiratory pattern on free‐breathing higher temporal resolution MRI stratifies patients by cardiopulmonary symptom burden. Study Type Prospective analysis of retrospectively acquired data. Subjects A total of 37 postacute Covid‐19 patients (25 male; median [interquartile range (IQR)] age: 58 [42–64] years; median [IQR] days from acute infection: 335 [186–449]). Field Strength/Sequence 0.55 T/two‐dimensional coronal true fast imaging with steady‐state free precession (trueFISP) at higher temporal resolution. Assessment Patients were stratified into three groups based on presence of no (N = 11), 1 (N = 14), or ≥2 (N = 14) cardiopulmonary symptoms, assessed using a standardized symptom inventory within 1 month of MRI. An automated lung postprocessing workflow segmented each lung in each trueFISP image (temporal resolution 0.2 seconds) and respiratory curves were generated. Quantitative parameters were derived including tidal lung area, rates of inspiration and expiration, lung area coefficient of variability (CV), and respiratory incoherence (departure from sinusoidal pattern) were. Pulmonary function tests were recorded if within 1 month of MRI. Qualitative assessment of respiratory pattern and lung opacity was performed by three independent readers with 6, 9, and 23 years of experience. Statistical Tests Analysis of variance to assess differences in demographic, clinical, and quantitative MRI parameters among groups; univariable analysis and multinomial logistic regression modeling to determine features predictive of patient symptom status; Akaike information criterion to compare the quality of regression models; Cohen and Fleiss kappa (κ) to quantify inter‐reader reliability. Two‐sided 5% significance level was used. Results Tidal area and lung area CV were significantly higher in patients with two or more symptoms than in those with one or no symptoms (area: 15.4 cm2 vs. 12.9 cm2 vs. 12.8 cm2; CV: 0.072, 0.067, and 0.058). Respiratory incoherence was significantly higher in patients with two or more symptoms than in those with one or no symptoms (0.05 vs. 0.043 vs. 0.033). There were no significant differences in patient age (P = 0.19), sex (P = 0.88), lung opacity severity (P = 0.48), or pulmonary function tests (P = 0.35–0.97) among groups. Qualitative reader assessment did not distinguish between groups and showed slight inter‐reader agreement (κ = 0.05–0.11). Data Conclusion Quantitative respiratory pattern measures derived from dynamic higher‐temporal resolution MRI have potential to stratify patients by symptom burden in a postacute Covid‐19 cohort. Level of Evidence 3 Technical Efficacy Stage 3

radiology, nuclear medicine & medical imaging
Longitudinal changes of diffusing capacity (DLCO) and dyspnoea after mild COVID-19

Nichici,T.,Beuter,H.,Stanko,K.,Russ,A.-K.,Reinke,L.,Nürnberger,C.,Störk,S.,Zoller,T.,Steinbeis,F.,Heim,E.,Hopff,S. M.,Vehreschild,J. J.,Heuschmann,P. U.,Lieb,W.,Franzpötter,K.,Poick,S.,Krawczak,M.,Abdo,M.,Rabe,K. F.,Heyckendorf,J.,Schreiber,S.,Watz,H.,Bahmer,T.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5260

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Post-Covid-Syndrome (PCS) can be quantified by the PCS severity score (PCSS, Bahmer T et al, eClinicalMedicine, 2022). It is based on 12 self-reported symptom complexes, including subjective dyspnoea, which may result from impaired diffusing capacity of the lung (DLCO). Objective: We aimed to quantify longitudinal DLCO changes in patients after mild COVID-19 based on PCS severity (PCSS hi vs. PCSS lo ). Methods : COVIDOM is a prospective cohort study of SARS-CoV-2 infected individuals, recruited ≥6 months after PCR confirmation with <10% hospitalization rate in total. Follow-Ups (FUs) were scheduled 12-18 months after PCR testing. Dyspnoea was assessed using a standardized questionnaire (MDP-A1), DLCO was measured according to ERS criteria. Results: 2,993 participants had complete lung function data at baseline (BL) with a mean DLCO of 95.15 %pred (z-score –0.37); 8.5% of these showed relevant impairments (DLCO<lln, 2012).="" gli="" in="" pcss hi vs. PCSS lo mean DLCO z-scores were –0.42±0.99 vs. –0.34±0.95 at BL and –0.54±0.95 vs. –0.38±1.00 at FU (all p>0.05). Median MDP-A1 differed significantly between both groups at BL (3 [IQR 1-5] vs. 0 [2-0]) and FU (2 [0-4] vs. 0 [1-0]) (all p<0.001). DLCO z-scores slightly worsened over time in both groups (p<0.05), while MDP-A1 scores improved in PCSS hi patients (p<0.05). Conclusion: In patients with mild acute COVID-19, marginal DLCO impairments did not differ between PCSS hi and PCSS lo at BL and FU. In contrast, PCSS hi patients had suffered more often from dyspnoea at BL, which markedly improved at FU, indicating that DLCO is not the appropriate measure to quantify breathlessness in PCS patients as reasons other than gas exchange impairment appear more relevant.

respiratory system
Radiological appearance and lung function six months after invasive ventilation in ICU for COVID-19 pneumonia: An observational follow-up study

Ylva Konsberg,Pawel Szaro,Anders Aneman,Sanna Kjellberg,Nektarios Solidakis,Sara Svedlund,Bengt Nellgård,Keti Dalla

DOI: https://doi.org/10.1371/journal.pone.0289603

IF: 3.7

2023-09-01

PLoS ONE

Abstract:Background Respiratory functional sequelae in COVID-19 patients admitted to the intensive care unit for invasive ventilation are sparsely reported. The aim of this study was to investigate the radiological lung appearance, lung function and their association at 6 months after hospital discharge. It was hypothesized that the degree of pathological morphology on CT scans would correlate with lung function at the time of follow-up. Methods and findings In this single-centre prospective observational study, 86 from 154 patients admitted to ICU due to COVID-19 between March 2020 and May 2021 were followed up at 6 months post discharge with computed tomography (CT) of the chest and pulmonary function tests (PFTs). The PFT results were expressed as z-scores calculated as the difference between the measured and predicted values divided by the standard deviation obtained from a reference population. Correlations were evaluated by Spearman’s rho including the 95% confidence interval. Pathological changes on CT were found in 78/85 participants with fibrous parenchymal bands being the most prevalent finding (91%) followed by traction bronchiectasis (64%) and ground glass opacities (41%). Sixty-five participants performed PFTs, and a restrictive pattern was the most prevalent abnormality (34%). Diffusing capacity of the lung for carbon monoxide (DLCO) was reduced in 66% of participants. The CT severity score weakly correlated with forced vital capacity (FVC) z-score (0.295, p = 0.006), DLCO z-score (-0.231, p = 0.032) and alveolar volume (VA) z-score (0.253, p = 0.019). Conclusions Most patients showed persistent radiological abnormalities on CT and reduced lung volumes, impaired diffusion capacity and patterns of restrictive lung function at 6 months post discharge from the ICU. The correlations between abnormalities on CT and lung function tests were weak. Further, studies with a long-term follow-up of lung function in this group of patients are needed.

multidisciplinary sciences
Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge

Oriol Sibila,Lídia Perea,Núria Albacar,Jorge Moisés,Tamara Cruz,Núria Mendoza,Belen Solarat,Gemma Lledó,Gerard Espinosa,Joan Albert Barberà,Joan Ramon Badia,Alvar Agustí,Jacobo Sellarés,Rosa Faner

DOI: https://doi.org/10.1186/s12931-022-01955-5

IF: 5.8

2022-02-21

Respiratory Research

Abstract:Abstract Background Some COVID-19 survivors present lung function abnormalities during follow-up, particularly reduced carbon monoxide lung diffusing capacity (DLCO). To investigate risk factors and underlying pathophysiology, we compared the clinical characteristics and levels of circulating pulmonary epithelial and endothelial markers in COVID-19 survivors with normal or reduced DLCO 6 months after discharge. Methods Prospective, observational study. Clinical characteristics during hospitalization, and spirometry, DLCO and plasma levels of epithelial (surfactant protein (SP) A (SP-A), SP-D, Club cell secretory protein-16 (CC16) and secretory leukocyte protease inhibitor (SLPI)), and endothelial (soluble intercellular adhesion molecule 1 (sICAM-1), soluble E-selectin and Angiopoietin-2) 6 months after hospital discharge were determined in 215 COVID-19 survivors. Results DLCO was < 80% ref. in 125 (58%) of patients, who were older, more frequently smokers, had hypertension, suffered more severe COVID-19 during hospitalization and refer persistent dyspnoea 6 months after discharge. Multivariate regression analysis showed that age ≥ 60 years and severity score of the acute episode ≥ 6 were independent risk factors of reduced DLCO 6 months after discharge . Levels of epithelial (SP-A, SP-D and SLPI) and endothelial (sICAM-1 and angiopoietin-2) markers were higher in patients with reduced DLCO, particularly in those with DLCO ≤ 50% ref. Circulating SP-A levels were associated with the occurrence of acute respiratory distress syndrome (ARDS), organizing pneumonia and pulmonary embolisms during hospitalization. Conclusions Reduced DLCO is common in COVID-19 survivors 6 months after hospital discharge, especially in those older than 60 years with very severe acute disease. In these individuals, elevated levels of epithelial and endothelial markers suggest persistent lung damage.

respiratory system
Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: a cross-sectional study

Dana Yelin,Nassem Ghantous,Muhammad Awwad,Vered Daitch,Talya Kalfon,Michal Mor,Shira Buchrits,Yair Shafir,Irit Shapira-Lichter,Leonard Leibovici,Dafna Yahav,Ili Margalit,Dorit Shitenberg

DOI: https://doi.org/10.1038/s41598-024-74404-6

IF: 4.6

2024-11-07

Scientific Reports

Abstract:Impaired pulmonary diffusing capacity for carbon monoxide (DLCO) following COVID-19 has been consistently reported among individuals recovering from severe-critical infection. However, most long COVID cases follow non-severe COVID-19. We assessed DLCO among individuals with long COVID recovering from mild to moderate acute illness. A cross-sectional study of adults with long COVID, assessed at a COVID recovery clinic > 3 months following the onset of acute infection, during 2020–2021. Participants subjectively ranked their dyspnea severity based on its impact on their daily living and underwent comprehensive pulmonary function testing (PFT). Clinical correlates for impaired DLCO (defined as < 80%) were assessed using multivariable logistic regression models. A total of 458 individuals, their mean age 45 (SD 16) and 246 (54%) of whom are women, were evaluated at an average of ~ 4 months following acute COVID-19. The most frequent PFT impairment was reduced DLCO, identified among 67 (17%) of the cohort. Clinical correlates of impaired DLCO included women (odds ration [OR] 3.64, 95% confidence interval [CI] 1.78–7.45, p < 0.001), cigarette smoking (OR 2.25, 95% CI 1.14–4.43, p = 0.019), and moderate-severe dyspnea (OR 2.77, 95% CI 1.39–5.50, p = 0.004). BMI inversely correlated with DLCO (OR 0.90, 95% CI 0.85–0.96 per 1 unit, p = 0.002). Impaired DLCO was not uncommon among individuals recovering from mild to moderate COVID-19. Women are at a greater risk, and subjective dyspnea correlated with impaired DLCO. Clinicians can rely on self-reported significant dyspnea to guide further assessment.

multidisciplinary sciences
Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up

Wei Qin,Shi Chen,Yunxia Zhang,Fen Dong,Zhu Zhang,Bingzhu Hu,Ziyang Zhu,Fajiu Li,Xiaojiang Wang,Yimin Wang,Kaiyuan Zhen,Jing Wang,YuLei Wan,Hongbo Li,Ismaïl Elalamy,Chenghong Li,Zhenguo Zhai,Chen Wang

DOI: https://doi.org/10.1183/13993003.03677-2020

IF: 24.3

2021-02-11

European Respiratory Journal

Abstract:Objective To evaluate pulmonary function and clinical symptoms in coronavirus disease 2019 (COVID-19) survivors within 3 months after hospital discharge, and to identify risk factors associated with impaired lung function. Methods and material COVID-19 patients were prospectively followed up with pulmonary function tests and clinical characteristics for 3 months following discharge from a hospital in Wuhan, China between January and February 2020. Results 647 patients were included. 87 (13%) patients presented with weakness, 63 (10%) with palpitation and 56 (9%) with dyspnea. Prevalences of the three symptoms were markedly higher in severe patients than non-severe patients (19% versus 10% for weakness, p=0.003; 14% versus 7% for palpitation, p=0.007; 12% versus 7% for dyspnea, p=0.014). Results of multivariable regression showed an increased odd in the ongoing symptoms among severe patients (OR: 1.7, 95%CI: 1.1–2.6, p=0.026) or patients with longer hospital stay (OR: 1.03, 95%CI: 1.00–1.05, p=0.041). Pulmonary function test results were available for 81 patients, including 41 non-severe and 40 severe patients. In this subgroup, 44 (54%) patients manifested abnormal diffusion capacity for carbon monoxide (DLCO) (68% severe versus 42% non-severe patients, p=0.019). Chest CT total severity score (TSS)>10.5 (OR: 10.4; 95%CI: 2.5–44.1; p=0.001) on admission and ARDS (OR: 4.6; 95%CI: 1.4–15.5; p=0.014) were significantly associated with impaired DLCO. Pulmonary interstitial damage may be associated with abnormal DLCO. Conclusion Pulmonary function, particularly DLCO, declined in COVID-19 survivors. This decrease was associated with TSS of chest CT >10.5 and ARDS occurrence. Pulmonary interstitial damage might contribute to the imparied DLCO.

respiratory system
Longitudinal Radiological Findings in Patients With COVID-19 With Different Severities: From Onset to Long-Term Follow-Up After Discharge

Yajing Zhao,Dongdong Wang,Nan Mei,Bo Yin,Xuanxuan Li,Yingyan Zheng,Anling Xiao,Xiangrong Yu,Xiaohui Qiu,Yiping Lu,Li Liu

DOI: https://doi.org/10.3389/fmed.2021.711435

IF: 3.9

2021-09-21

Frontiers in Medicine

Abstract:Objective: This study aimed to investigate the evolution of radiological findings in the patients with coronavirus disease 2019 (COVID-19) pneumonia with different severities from onset to 1-year follow-up and identify the predictive factors for different pulmonary lesion absorption status in the patients infected with COVID-19. Methods: A retrospective study was performed on the clinical and radiological features of 175 patients with COVID-19 pneumonia hospitalized at three institutions from January 21 to March 20, 2020. All the chest CT scans during hospitalization and follow-ups after discharge were collected. The clinical and radiological features from the chest CT scans both at the peak stage and before discharge from the hospital were used to predict whether the pulmonary lesions would be fully absorbed after discharge by Cox regression. Then, these patients were stratified into two groups with different risks of pulmonary lesion absorption, and an optimal timepoint for the first CT follow-up was selected accordingly. Results: A total of 132 (75.4%) patients were classified into the non-severe group, and 43 (24.6%) patients were classified into the severe group, according to the WHO guidelines. The opacification in both the groups changed from ground-glass opacity (GGO) to consolidation and then from consolidation to GGO. Among the 175 participants, 135 (112 non-severe and 23 severe patients with COVID-19) underwent follow-up CT scans after discharge. Pulmonary residuals could be observed in nearly half of the patients (67/135) with the presentation of opacities and parenchymal bands. The parenchymal bands in nine discharged patients got fully absorbed during the follow-up periods. The age of patient [hazard ratio ( HR ) = 0.95, 95% CI , 0.95–0.99], level of lactate dehydrogenase (LDH) ( HR = 0.99; 95% CI , 0.99–1.00), level of procalcitonin ( HR = 8.72; 95% CI , 1.04–73.03), existence of diffuse lesions ( HR = 0.28; 95% CI , 0.09–0.92), subpleural distribution of lesions ( HR = 2.15; 95% CI, 1.17–3.92), morphology of residuals (linear lesion: HR = 4.58, 95% CI , 1.22–17.11; nodular lesion: HR = 33.07, 95% CI , 3.58–305.74), and pleural traction ( HR = 0.41; 95% CI , 0.22–0.78) from the last scan before discharge were independent factors to predict the absorption status of COVID-19-related pulmonary abnormalities after discharge. According to a Kaplan–Meier analysis, the probability of patients of the low-risk group to have pulmonary lesions fully absorbed within 90 days reached 91.7%. Conclusion: The development of COVID-19 lesions followed the trend from GGO to consolidation and then from consolidation to GGO. The CT manifestations and clinical and laboratory variables before discharge could help predict the absorption status of pulmonary lesions after discharge. The parenchymal bands could be fully absorbed in some COVID-19 cases. In this study, a Cox regression analysis indicated that a timepoint of 3 months since onset was optimal for the radiological follow-up of discharged patients.

medicine, general & internal
Evaluation of the pulmonary function of patients with severe coronavirus 2019 disease three months after diagnosis.

M. Baldini,M. Chiapella,H. Sala,S. Guardia,A. Fernandez.

Medicina

Abstract:There are few data regarding the repercussion in the pulmonary function of patients who had severe or critical COVID-19 pneumonia. The objective was to describe these patients' pulmonary function and establish an association with the severity of the disease (patients with severe or critical pneumonia), the presence of comorbidities, the tomographic involvement and the persistence of dyspnoea. Fifty-five patients were included, 40 (73%) male, media of age 54.9 (11.6) years old and body mass index (BMI) 33.1 (6.09) kg/ m2. Fifty (90%) had 1 comorbidity, obesity 67%, arterial hypertension 36%, and diabetes mellitus 35%. Twentyfive (45%) had critical pneumonia. Fifteen (27%) had a spirometric alteration that suggested restriction and 32 (58%) had gas exchange defect. The latter had forced volume capacity (FVC), forced expiratory volume in the first second (FEV1) and carbon monoxide diffusion capacity (DLCO) values significantly lower. Ninety percent presented some degree of involvement in the chest CT scan, ground glass-opacities the most frequent finding. A moderate negative correlation was found between the severity of the tomographic involvement and the DLCO levels. Thirty patients (55%) referred some degree of dyspnoea. Patients with this symptom had DLCO and KCO values below those who did not have dyspnoea: 70.5 vs. 85.1 p = 0.02 and 88 vs. 104 p = 0.02. The presence of abnormal gas exchange is the main characteristic of patients with pulmonary sequelae due to COVID-19. Our study does not show either predictor of evolution towards pulmonary sequelae or an association with the severity of the disease.

Medicine
Diagnostic performance of radiologists in distinguishing post-COVID-19 residual abnormalities from interstitial lung abnormalities

Jong Eun Lee,Hyo-Jae Lee,Gyeryeong Park,Kum Ju Chae,Kwang Nam Jin,Eva Castañer,Benoit Ghaye,Jane P Ko,Helmut Prosch,Scott Simpson,Anna Rita Larici,Jeffrey P Kanne,Thomas Frauenfelder,Yeon Joo Jeong,Soon Ho Yoon

DOI: https://doi.org/10.1007/s00330-024-11075-x

2024-09-23

Abstract:Objective: Distinguishing post-COVID-19 residual abnormalities from interstitial lung abnormalities (ILA) on CT can be challenging if clinical information is limited. This study aimed to evaluate the diagnostic performance of radiologists in distinguishing post-COVID-19 residual abnormalities from ILA. Methods: This multi-reader, multi-case study included 60 age- and sex-matched subjects with chest CT scans. There were 40 cases of ILA (20 fibrotic and 20 non-fibrotic) and 20 cases of post-COVID-19 residual abnormalities. Fifteen radiologists from multiple nations with varying levels of experience independently rated suspicion scores on a 5-point scale to distinguish post-COVID-19 residual abnormalities from fibrotic ILA or non-fibrotic ILA. Interobserver agreement was assessed using the weighted κ value, and the scores of individual readers were compared with the consensus of all readers. Receiver operating characteristic curve analysis was conducted to evaluate the diagnostic performance of suspicion scores for distinguishing post-COVID-19 residual abnormalities from ILA and for differentiating post-COVID-19 residual abnormalities from both fibrotic and non-fibrotic ILA. Results: Radiologists' diagnostic performance for distinguishing post-COVID-19 residual abnormalities from ILA was good (area under the receiver operating characteristic curve (AUC) range, 0.67-0.92; median AUC, 0.85) with moderate agreement (κ = 0.56). The diagnostic performance for distinguishing post-COVID-19 residual abnormalities from non-fibrotic ILA was lower than that from fibrotic ILA (median AUC = 0.89 vs. AUC = 0.80, p = 0.003). Conclusion: Radiologists demonstrated good diagnostic performance and moderate agreement in distinguishing post-COVID-19 residual abnormalities from ILA, but careful attention is needed to avoid misdiagnosing them as non-fibrotic ILA. Key points: Question How good are radiologists at differentiating interstitial lung abnormalities (ILA) from changes related to COVID-19 infection? Findings Radiologists had a median AUC of 0.85 in distinguishing post-COVID-19 abnormalities from ILA with moderate agreement (κ = 0.56). Clinical relevance Radiologists showed good diagnostic performance and moderate agreement in distinguishing post-COVID-19 residual abnormalities from ILA; nonetheless, caution is needed in distinguishing residual abnormalities from non-fibrotic ILA.
Clinico-radiological and pulmonary function assessment of post-COVID-19 patients with respiratory symptoms

Nilakantha Behera,Jeetendra Kumar Patra,Bijay Kumar Dash,Manoranjan Pattnaik,Deepak Sahu,Bayyaram Rambhoopal Reddy

DOI: https://doi.org/10.4103/jfmpc.jfmpc_1721_23

Abstract:Background: Respiratory symptoms may persist for several weeks following the initial coronavirus disease 2019 (COVID-19) infection. The aims and objectives were to assess the clinical symptoms, pulmonary functions, and radiological changes and to assess the cardio-vascular complications in post-COVID-19 patients. Methods: This observational study was conducted in the Department of Pulmonary Medicine in collaboration with the Department of Cardiology, SCBMCH, Cuttack, from March 2021 to August 2022 on 75 post-COVID-19 patients with respiratory symptoms from 4 weeks to 2 years after treatment for COVID-19 infection. Post-COVID patients having previous respiratory diseases were excluded from the study. Results: Among 75 patients, the most common age group was 18-30 years with a male-to-female ratio of 2.5:1. Based on O2 requirement, patients were divided into the mild symptomatic group and moderate to severe pneumonia group. The most common respiratory symptom was dyspnea, followed by cough with expectoration. Bilateral crepitations were found in 17% of cases. C-reactive protein (CRP) and D-dimer were increased in 38.6% and 32% of patients, respectively. 42.6% had abnormal chest X-ray, and the most common abnormal finding was reticular thickening. In spirometry, the restrictive pattern and mixed pattern were the predominant types documented in 49.3% and 13.3% of cases, respectively, which were significant in the moderate-severe group. Diffusion capacity of the lungs for carbon monoxide (DLCO) was performed in only 19 patients (mild group 13 and moderate-severe group 6). Twelve (63.2%) patients had abnormal DLCO. P- values were significant for RV (0.0482) and RV/TLC (0.0394). High-resolution computed tomography (HRCT) of the thorax was abnormal in 55.7% with the most common abnormalities as inter- and intra-lobular septal thickening. The left ventricular ejection fraction was preserved in all patients, with right atrium and right ventricle enlargement in 2.6% and pulmonary hypertension in 4.0% of participants. Conclusion: All post-COVID-19 patients having respiratory symptoms after recovery from acute COVID-19 may be referred by family care physicians to a dedicated post-COVID center for further evaluation, management, and early rehabilitation to decrease the morbidity in recovered patients. Persistent increased blood parameters like TLC, N/L ratio, RBS, CRP, and D-dimer seen in recovered post-COVID-19 patients. The long-term impact of CT findings on respiratory symptoms, pulmonary functions, and quality of life is unknown. Cardiovascular abnormalities in post-COVID-19 patients are infrequent.
Association of Initial Symptoms or Comorbidities With Pneumonia Lesions in COVID-19 Patients: Based on Artificial Intelligence-Enabled CT Quantitation

Fangzhengyuan Yuan,Chuan Liu,Jie Yang,Hu Tan,Shizhu Bian,Xubin Gao,Jihang Zhang,Mingdong Hu,Renzheng Chen,Yang Shen,Jingbin Ke,Yuanqi Yang,Chunyan He,Ran Cheng,Lan Huang

DOI: https://doi.org/10.21203/rs.3.rs-78075/v1

2020-09-18

Abstract:Abstract Background: Coronavirus disease 2019 (COVID-19) patients with a larger ratio of pneumonia lesions are more likely to progress to acute respiratory distress syndrome and death. This study aimed to investigate the relationship of baseline parameters with pneumonia lesions on admission, as quantified by an artificial intelligence (AI) algorithm using computed tomography (CT) images. Methods: This retrospective study quantitatively assessed lung lesions on CT using an AI algorithm in 1630 consecutive patients confirmed with COVID-19 on admission and classified the patients into none (0%), mild (>0–25%), intermediate (>25–50%), and severe (>50%) groups, according to the lesion ratio of the whole lung. A multivariate linear regression model was established to explore the relationship between the lesion ratio and laboratory parameters. The baseline parameters associated with lung lesions, including demographics, initial symptoms, and comorbidities, were determined using a multivariate ordinal regression model. Results: The 1630 patients confirmed with COVID-19 had a median whole lung lesion ratio of 4.1%, and the right lower lung lobe had the most lesions among the five lung lobes based on the evaluation of CT using AI algorithm. The whole lung lesion ratio was associated with the levels of plasma fibrinogen (r=0.280, p<0.001), plasma D-dimer (r=0.248, p<0.001), serum α-hydroxybutyrate dehydrogenase (r=0.363, p<0.001), serum albumin (r=-0.300, p<0.001), and peripheral blood leukocyte count (r=0.194, p<0.001). Among the four patients groups categorised by whole lung lesion ratio, the highest frequency of cough (p<0.001) and shortness of breath (p<0.001) were found in the severe group, and the highest frequency of hypertension (p<0.001), diabetes (p<0.001) and anemia (p=0.039) were observed in the intermediate group. Based on baseline ordinal regression analysis, cough (p=0.009), shortness of breath (p<0.001), hypertension (p=0.002), diabetes (p=0.005), and anemia (p=0.006) were independent risk factors for more severe lung lesions. Conclusions: Based on AI-enabled CT quantitation , patients with initial symptoms of cough/shortness of breath, or with comorbidities of hypertension, diabetes, or anemia, had a higher risk for more severe lung lesions on admission in COVID-19 patients.
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Xiaojun Wu,Xiaofan Liu,Yilu Zhou,Hongying Yu,Ruiyun Li,Qingyuan Zhan,Fang Ni,Si Fang,Yang Lu,Xuhong Ding,Hailing Liu,Rob M Ewing,Mark G Jones,Yi Hu,Hanxiang Nie,Yihua Wang

DOI: https://doi.org/10.1016/S2213-2600(21)00174-0

Abstract:Background: The consequences of COVID-19 in those who recover from acute infection requiring hospitalisation have yet to be clearly defined. We aimed to describe the temporal trends in respiratory outcomes over 12 months in patients hospitalised for severe COVID-19 and to investigate the associated risk factors. Methods: In this prospective, longitudinal, cohort study, patients admitted to hospital for severe COVID-19 who did not require mechanical ventilation were prospectively followed up at 3 months, 6 months, 9 months, and 12 months after discharge from Renmin Hospital of Wuhan University, Wuhan, China. Patients with a history of hypertension; diabetes; cardiovascular disease; cancer; and chronic lung disease, including asthma or chronic obstructive pulmonary disease; or a history of smoking documented at time of hospital admission were excluded at time of electronic case-note review. Patients who required intubation and mechanical ventilation were excluded given the potential for the consequences of mechanical ventilation itself to influence the factors under investigation. During the follow-up visits, patients were interviewed and underwent physical examination, routine blood test, pulmonary function tests (ie, diffusing capacity of the lungs for carbon monoxide [DLCO]; forced expiratory flow between 25% and 75% of forced vital capacity [FVC]; functional residual capacity; FVC; FEV1; residual volume; total lung capacity; and vital capacity), chest high-resolution CT (HRCT), and 6-min walk distance test, as well as assessment using a modified Medical Research Council dyspnoea scale (mMRC). Findings: Between Feb 1, and March 31, 2020, of 135 eligible patients, 83 (61%) patients participated in this study. The median age of participants was 60 years (IQR 52-66). Temporal improvement in pulmonary physiology and exercise capacity was observed in most patients; however, persistent physiological and radiographic abnormalities remained in some patients with COVID-19 at 12 months after discharge. We found a significant reduction in DLCO over the study period, with a median of 77% of predicted (IQR 67-87) at 3 months, 76% of predicted (68-90) at 6 months, and 88% of predicted (78-101) at 12 months after discharge. At 12 months after discharge, radiological changes persisted in 20 (24%) patients. Multivariate logistic regression showed increasing odds of impaired DLCO associated with female sex (odds ratio 8·61 [95% CI 2·83-26·2; p=0·0002) and radiological abnormalities were associated with peak HRCT pneumonia scores during hospitalisation (1·36 [1·13-1·62]; p=0·0009). Interpretation: In most patients who recovered from severe COVID-19, dyspnoea scores and exercise capacity improved over time; however, in a subgroup of patients at 12 months we found evidence of persistent physiological and radiographic change. A unified pathway for the respiratory follow-up of patients with COVID-19 is required. Funding: National Natural Science Foundation of China, UK Medical Research Council, and National Institute for Health Research Southampton Biomedical Research Centre. Translation: For the Chinese translation of the abstract see Supplementary Materials section.
Residual lung abnormalities after 12 months of COVID19 hospitalization: A brazilian multicenter study

Lafeta,M. L.,Souza,V. C.,Penido,F. O.,Saldanha,M. F.,Prudente,R. A.,Brizola,L. F. P.,Franco,E. A. T.,Folchino,F. N.,Lopes,E. B. R. R.,Albuquerque,A. L. P.,Tanni,S. E.,Izbicki,M.,Nery,L. E.,Oliveira,R. K. F.,Sperandio,P. A.,Ferreira,E. V.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5264

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Patients hospitalized due to hypoxemic COVID19 have a higher risk of residual fibrotic pulmonary sequelae. During follow-up, studies have demonstrated decreased lung function, especially reduced DLCO. Objective: To evaluate pulmonary function tests (PFTs) after 12 months of COVID19 hospitalization to identify lung sequelae and the risk factors for low DLCO. Methods: Observational, prospective, multicenter study of COVID-19 hospitalized patients between Mar,20-Nov,21. Patients underwent PFTs and 6-minute walking test(6MWT) after 12months of symptom onset. Results:708 patients were included, and 285 were re-evaluated after 12months. 55% were male, 58±12years, and 45% in ICU. 185 performed spirometry and 118 lung volumes/DLCO: 25% had FVC≤80%pred, 31% TLC≤80%pred, 49% DLCO≤80%pred. In the 6MWT (n=190) mean distance was 448±96m and 33% had desaturation ≥4points. Patients with DLCO≤80%pred were older (p<0.001),but had no differences in hospitalization severity. In PFTs, patients with DLCO≤80%pred had lower FVC%pred(85±14vs94±14;p<0.001), TLC%pred(80±14vs91±14;p<0.001),KCO%pred(86±19vs99±15;p 80%pred. In the multivariate logistic analysis, DLCO≤80%pred were related to age ≥60years [1.48-9.89;p=0.006] and FVC≤80%pred [1.29–8.80;p=0.013]. Conclusion:After 12 months of follow-up, there was an improvement in PFTs, however almost 50% persisted with low DLCO. The reduced DLCO, VA and KCO associated with preserved VA/TLC suggest a fibrosing sequelae profile. Older patients with restrictive ventilatory patterns had a higher risk of reduced DLCO and need to be continued follow-up.

respiratory system
An elevated level of circulating galanin promotes developmental expression of myelin basic protein in the mouse brain

H. Lyubetska,L. Zhang,J. Kong,M. Vrontakis

DOI: https://doi.org/10.1016/j.neuroscience.2014.10.031

IF: 3.708

2015-01-22

Neuroscience

Abstract:
Medium-term chest computed tomography (CT) follow-up of COVID-19 pneumonia patients after recovery to assess the rate of resolution and determine the potential predictors of persistent lung changes

Arshed Hussain Parry,Abdul Haseeb Wani,Naveed Nazir Shah,Majid Jehangir

DOI: https://doi.org/10.1186/s43055-021-00434-z

2021-02-16

Egyptian Journal of Radiology and Nuclear Medicine

Abstract:Abstract Background The data on medium-term follow-up of coronavirus disease-19 (COVID-19) pneumonia survivors is scarce. Medium-term follow-up will generate knowledge and help in devising a structured follow-up plan and to facilitate enrolment in clinical trials assessing the role of antifibrotic drugs in modifying the course of disease in order to avert long-term pulmonary sequelae of disease. The study was aimed to evaluate the lung findings on a medium-term follow-up (3 months or more) chest computed tomography (CT) in COVID-19 pneumonia survivors, assess the rate of resolution or persistence of lung abnormalities and to identify the initial demographic, clinical, and imaging characteristics that could potentially predict the persistence of lung abnormalities on follow-up. Results Out of the total study cohort of 81 patients, 46 (56.8%) demonstrated complete resolution of lung findings and the remaining 35 (43.2%) had residual lung opacities on follow-up CT. The most common type of residual abnormality was ground glass opacity (GGO) (16/35; 45.7%), followed by parenchymal bands (9/35; 25.7%), mixed pattern of GGO and parenchymal bands (6/35; 17.2%), bronchiectasis (6/35; 17.2%), and interlobular septal thickening (4/35; 11.4%). Patients with residual abnormalities were older, had higher BMI, more comorbidities, lower SpO2, longer hospital stay, higher rate of intensive care unit (ICU) admission, higher WBC count, a higher CT severity score, and lower rate of steroid administration with all p values < 0.05. Conclusion Nearly half of post-COVID-19 survivors had residual lung abnormalities after ≥ 3 months of follow-up. Certain clinico-radiological characteristics have the potential to identify the individuals at risk of having residual lung abnormalities on medium-term follow-up.
Persistence of post-COVID lung parenchymal abnormalities during the three-month follow-up

Ali Bin Sarwar Zubairi,Anjiya Shaikh,Syed Muhammad Zubair,Akbar Shoukat Ali,Safia Awan,Muhammad Irfan

DOI: https://doi.org/10.5603/ARM.a2021.0090

Abstract:Introduction: COVID-19-associated pulmonary sequalae have been increasingly reported after recovery from acute infection. Therefore, we aim to explore the charactersitics of persistent lung parenchymal abnormalities in patients with COVID-19. Material and methods: An observational study was conducted in patients with post-COVID lung parenchymal abnormalities from April till September 2020. Patients ≥18 years of age with COVID-19 who were diagnosed as post-COVID lung parenchymal abnormality based on respiratory symptoms and HRCT chest imaging after the recovery of acute infection. Data was recorded on a structured pro forma, and descriptive analysis was performed using Stata version 12.1. Results: A total of 30 patients with post-COVID lung parenchymal abnormalities were identified. The mean age of patients was 59.1 (SD 12.6), and 27 (90.0%) were males. Four HRCT patterns of lung parenchymal abnormalities were seen; organizing pneumonia in 10 (33.3%), nonspecific interstitial pneumonitis in 17 (56.7%), usual interstitial pneumonitis in 12 (40.0%) and probable usual interstitial pneumonitis in 14 (46.7%). Diffuse involvement was found in 15 (50.0%) patients, while peripheral predominance in 15 (50.0%), and other significant findings were seen in 8 (26.7%) patients. All individuals were treated with corticosteroids. The case fatality rate was 16.7%. Amongst the survivors, 32.0% recovered completely, 36.0% improved, while 32.0% of the patients had static or progressive disease. Conclusion: This is the first study from Southeast Asia that identified post-COVID lung parenchymal abnormalities in patients who had no pre-existing lung disease highlighting the importance of timely recognition and treatment of this entity that might lead to fatal outcome.
Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with Coronavirus 2019 (COVID-19) Pneumonia

Da Hyun Kang,Grace Hyun J. Kim,Sa-Beom Park,Song-I Lee,Jeong Suk Koh,Matthew S. Brown,Fereidoun Abtin,Michael F. McNitt-Gray,Jonathan G. Goldin,Jeong Seok Lee

DOI: https://doi.org/10.3390/biomedicines12010120

IF: 4.757

2024-01-06

Biomedicines

Abstract:Coronavirus disease 2019 (COVID-19), is an ongoing issue in certain populations, presenting rapidly worsening pneumonia and persistent symptoms. This study aimed to test the predictability of rapid progression using radiographic scores and laboratory markers and present longitudinal changes. This retrospective study included 218 COVID-19 pneumonia patients admitted at the Chungnam National University Hospital. Rapid progression was defined as respiratory failure requiring mechanical ventilation within one week of hospitalization. Quantitative COVID (QCOVID) scores were derived from high-resolution computed tomography (CT) analyses: (1) ground glass opacity (QGGO), (2) mixed diseases (QMD), and (3) consolidation (QCON), and the sum, quantitative total lung diseases (QTLD). Laboratory data, including inflammatory markers, were obtained from electronic medical records. Rapid progression was observed in 9.6% of patients. All QCOVID scores predicted rapid progression, with QMD showing the best predictability (AUC = 0.813). In multivariate analyses, the QMD score and interleukin(IL)-6 level were important predictors for rapid progression (AUC = 0.864). With >2 months follow-up CT, remained lung lesions were observed in 21 subjects, even after several weeks of negative reverse transcription polymerase chain reaction test. AI-driven quantitative CT scores in conjugation with laboratory markers can be useful in predicting the rapid progression and monitoring of COVID-19.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Relationship between Lung and Brain Injury in COVID-19 Patients: A Hyperpolarized 129Xe-MRI-based 8-Month Follow-Up

Shizhen Chen,Yina Lan,Haidong Li,Liming Xia,Chaohui Ye,Xin Lou,Xin Zhou

DOI: https://doi.org/10.3390/biomedicines10040781

IF: 4.757

2022-03-27

Biomedicines

Abstract:Although the lungs are the primary organ involved, increasing evidence supports the neuroinvasive potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study investigates the potential relationship between coronavirus disease (COVID-19)-related deterioration of brain structure and the degree of damage to lung function. Nine COVID-19 patients were recruited in critical condition from Jin Yin-tan Hospital (Wuhan, China) who had been discharged between 4 February and 27 February 2020. The demographic, clinical, treatment, and laboratory data were extracted from the electronic medical records. All patients underwent chest CT imaging, 129Xe gas lung MRI, and 1H brain MRI. Four of the patients were followed up for 8 months. After nearly 12 months of recovery, we found no significant difference in lung ventilation defect percentage (VDP) between the COVID-19 group and the healthy group (3.8 ± 2.1% versus 3.7 ± 2.2%) using 129Xe MRI, and several lung-function-related parameters—such as gas–blood exchange time (T)—showed improvement (42.2 ms versus 32.5 ms). Combined with 1H brain MRI, we found that the change in gray matter volume (GMV) was strongly related to the degree of pulmonary function recovery—the greater the increase in GMV, the higher degree of pulmonary function damage.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

Demonstration of a low-molecular-weight natriuretic factor in uremic serum.

Longitudinal Clinical and Radiographic Evaluation Reveals Interleukin-6 As an Indicator of Persistent Pulmonary Injury in COVID-19

Impact of Coronavirus Disease 2019 on Pulmonary Function in Early Convalescence Phase

Quantitative Characterization of Respiratory Patterns on Dynamic Higher Temporal Resolution MRI to Stratify Postacute Covid‐19 Patients by Cardiopulmonary Symptom Burden

Longitudinal changes of diffusing capacity (DLCO) and dyspnoea after mild COVID-19

Radiological appearance and lung function six months after invasive ventilation in ICU for COVID-19 pneumonia: An observational follow-up study

Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge

Pulmonary diffusing capacity among individuals recovering from mild to moderate COVID-19: a cross-sectional study

Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up

Longitudinal Radiological Findings in Patients With COVID-19 With Different Severities: From Onset to Long-Term Follow-Up After Discharge

Evaluation of the pulmonary function of patients with severe coronavirus 2019 disease three months after diagnosis.

Diagnostic performance of radiologists in distinguishing post-COVID-19 residual abnormalities from interstitial lung abnormalities

Clinico-radiological and pulmonary function assessment of post-COVID-19 patients with respiratory symptoms

Association of Initial Symptoms or Comorbidities With Pneumonia Lesions in COVID-19 Patients: Based on Artificial Intelligence-Enabled CT Quantitation

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Residual lung abnormalities after 12 months of COVID19 hospitalization: A brazilian multicenter study

An elevated level of circulating galanin promotes developmental expression of myelin basic protein in the mouse brain

Medium-term chest computed tomography (CT) follow-up of COVID-19 pneumonia patients after recovery to assess the rate of resolution and determine the potential predictors of persistent lung changes

Persistence of post-COVID lung parenchymal abnormalities during the three-month follow-up

Quantitative Computed Tomography Lung COVID Scores with Laboratory Markers: Utilization to Predict Rapid Progression and Monitor Longitudinal Changes in Patients with Coronavirus 2019 (COVID-19) Pneumonia

Relationship between Lung and Brain Injury in COVID-19 Patients: A Hyperpolarized 129Xe-MRI-based 8-Month Follow-Up